These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Author: Garthwaite E, Bhandari S.
    Journal: Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582.
    Abstract:
    Hyperkalemia is exacerbated by angiotensin converting enzyme inhibitors (ACE-I). Distal potassium (K(+)) secretion is negligible in anuric patients. ACE-I therapy may reduce renal, peritoneal, and colonic K(+) losses. We examined the effect of ACE-I therapy on serum, urinary, and dialysate K(+) in a cross-section of peritoneal and hemodialysis patients. Serum, 24-h urine K(+), and peritoneal dialysate excretion K(+) levels were measured and the results were compared in the various dialysis and treatment groups. Eighty-one hemodialysis (HD) and 32 peritoneal dialysis (PD) patients were included. Serum K(+) in HD patients with no residual renal function (RRF) was higher in those receiving ACE-I therapy (P = 0.02). Serum K(+) levels in HD patients receiving ACE-I treatments with RRF was similar to that in oligoanuric HD patients not receiving an ACE-I. Urinary K(+) excretion was significantly reduced in those on ACE-I therapy versus those not on an ACE-I (P < 0.05). Mean serum K(+) was lower in PD versus HD patients (P < 0.05). PD patients with no RRF on ACE-I therapy had higher serum K(+) concentrations (P = 0.002) and dialysate K(+) excretion was lower (P = 0.05), in comparison with PD patients not on an ACE-I. PD patients with RRF on ACE-I therapy had higher serum K(+) concentrations compared with those not on ACE-I therapy (P = 0.03). Both urinary and dialysate K(+) excretion were reduced (P = 0.001 and P = 0.002, respectively). ACE-I therapy increases serum K(+) concentration in dialysis patients. PD patients have relatively lower serum K(+) levels compared with HD patients. In PD patients, ACE-I therapy reduces dialysate K(+). These changes may result from reduced peritoneal movement of K(+).
    [Abstract] [Full Text] [Related] [New Search]